bioAffinity Technologies, Inc. (BIAF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 113.75k | -- | 1946 |
| Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 299.17k | -- | 1956 |
| Mr. Michael Dougherty CPA, M.B.A. | VP & CFO | 238.92k | -- | 1979 |
| Mr. Xavier T. Reveles M.S. | Chief Operating Officer | -- | -- | 1970 |
| Dr. Vivienne I. Rebel M.D., Ph.D. | Executive VP and Chief Medical & Science Officer | 238.39k | -- | 1966 |
| Mr. Timothy P. Zannes J.D. | Executive VP, Secretary & General Counsel | -- | -- | 1953 |
| Ms. Julie Anne Overton | Director of Communications | -- | -- | -- |
| Mr. Dallas J. Coleman | National Director of Sales | -- | -- | -- |
| Dr. William Bauta Ph.D. | Senior Vice President of Therapeutics | -- | -- | -- |
bioAffinity Technologies, Inc.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
April 11, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
April 5, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
April 2, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing